Introduction
============

Phenylketonuria (PKU) is the most common inborn error of amino acid metabolism and shows autosomal recessive inheritance. Mutations in the gene encoding phenylalanine hydroxylase (*PAH*; EC1.14.16.1) cause phenylalanine accumulation in the body fluids and damage to the central nervous system that can result in severe mental retardation and neurobehavioral abnormalities ([@b18-gmb-35-709]). PKU, which was first described by Folling in 1934, is a worldwide disease with marked regional and ethnic variation in its incidence. The prevalence is high among whites and low amongst blacks and asians ([@b4-gmb-35-709]). A prevalence of 1 in 10,000 was reported in Caucasians ([@b14-gmb-35-709]) while that in Indians was approximately 1:18,300 ([@b13-gmb-35-709]). PKU is more frequent in Tunisia (1:7,631) ([@b7-gmb-35-709]). The incidence of PKU varies considerably across China, with an overall prevalence of 1:11,144 from 1985 to 2001 ([@b5-gmb-35-709]). The prevalence in the provinces of Shanxi, Jiangxi, Heilongjiang and Shandong was reported to be 1:7,849 ([@b9-gmb-35-709]), 1:11,188 ([@b16-gmb-35-709]), 1:5,346 ([@b10-gmb-35-709]) and 1:7,408 ([@b2-gmb-35-709]), respectively. The incidence among neonates in Shanxi province from 2004 to 2009 was 1:3,425 ([@b26-gmb-35-709]), which suggests that the incidence in northern China is higher than in southern China.

The *PAH* gene was first cloned in 1983 ([@b17-gmb-35-709]). To date, 564 mutations of the *PAH* gene (12q22--q24) have been deposited in the PAH Mutation Analysis Consortium Database, of which 60.5% are missense mutations, 13.5% are deletion mutations, 11% are splicing mutations and 5.0% are nonsense mutations, inserts and silent mutations. The *PAH* gene mutations show considerable ethnic and regional variation ([@b20-gmb-35-709]). In the present study, we examined the variation in mutations in exons 3, 6, 7, 11 and 12 of the PAH gene in 59 children with PKU from Shanxi province.

Subjects and Methods
====================

Subjects
--------

Fifty-nine unrelated children with PKU were recruited for this study after obtaining informed consent from the parents. The patients (30 males, 29 females) were identified during treatment at the Neonatal Screening Center of the Shanxi Province Women and Childrens Hospital in Taiyuan and came from various regions of Shanxi province. The subjects were ≤ 10 years old and were classified as \< 2 years old (n = 38), 2--6 years old (n = 18) and 6--10 years old (n = 3). All 59 cases exhibited significant clinical manifestations of PKU and fulfilled the diagnostic criteria for PKU, with blood phenylalanine concentrations \> 20 mg/dL ([@b12-gmb-35-709]). Urinary pterin analysis and blood neopterin dihydropteridine reductase assays were used to exclude tetrahydrobiopterin deficiency. Twenty-five patients were placed on a low Phe diet to decrease Phe levels following the initial diagnosis. The healthy children included 53 males and 47 females, with ages ranging from 1 month to 10 years old. This study was approved by Taiyuan Centre Hospital Ethical Comimittee.

DNA extraction
--------------

Genomic DNA was extracted from peripheral blood using a DNA extraction kit (Shanghai Ying Jun Biotechnology Co., Ltd., Shanghai, China). Purity was assessed by electrophoresis in 1% agarose gels and the DNA was stored at −20 °C.

PCR amplification
-----------------

Exons 3, 6, 7, 11 and 12 of the PAH gene were amplified. The primers for exons 3, 6, 11 and 12 were based on a previous report ([@b4-gmb-35-709]) whereas those for exon 7 were designed specifically for this study. All primers were synthesized by Shanghai Jin Kang Biotechnology (Shanghai, China) ([Table 1](#t1-gmb-35-709){ref-type="table"}). The PCR mixture consisted of 10X buffer, 2.5 mM Mg^2+^, 0.2 mM dNTP, 0.5 μM primer, 1 U of *Taq* polymerase and 1 μL of template DNA in a total volume of 20 μL. The reaction conditions were: denaturation at 94 °C for 3 min followed by 35 cycles of amplification at 94 °C for 30 s and annealing ([Table 1](#t1-gmb-35-709){ref-type="table"}) for 30 s with a final extension at 72 °C for 5 min. The PCR products were detected by electrophoresis in 2% agarose gels.

Sequencing
----------

The PCR products were sequenced by Shanghai Ying Jun Biotechnology (Shanghai, China) and compared with the human genomic DNA sequence in GenBank to identify the mutations.

Statistical analysis
--------------------

All statistical analyses, including the χ^2^-test, were done using SPSS 13.0 statistical software. A p value ≤ 0.05 indicated significance.

Results
=======

Exons 3, 6, 7, 11 and 12 of the PAH gene from 59 children with PKU and 100 healthy children were aligned with the GenBank cDNA sequence (GI: 209364518) of the PAH gene. Three single nucleotide polymorphisms (SNPs) \[Q232 (CAA→CAG), V245V (GTG→GTA), and L385L (CTG→CTC)\] were identified in the patients and healthy children. The incidence of the 696 locus SNP in children with PKU (96.2%) was not significantly different from that in healthy children (97%; χ^2^ = 0.79, p \> 0.05). Similarly, there was no significant difference in the incidence of the 735 locus SNP in the patients compared to the healthy controls (76.1% *vs.* 77.3%; (χ^2^ = 0.327, p \> 0.05) or in the incidence of the 1155 locus SNP (7.6% in patients *vs.* 8.3% in healthy controls; χ^2^ = 0.111, p \> 0.05).

In children with PKU, 81 mutations belonging to 16 different types of mutations were observed and accounted for 61% of the PAH gene mutations. The mutations R111X, H64 \> TfsX9 and S70 deletion were found in exon 3, with frequencies of 5.1%, 0.8% and 0.8%, respectively. Only the EX6-96A \> G mutation was found in exon 6, with a frequency of 10.2%. The R234Q mutation in exon 7 had the highest frequency followed by Ivs7 + 2 T \> A (5.1%) and T278I (2.5%). G247V, R252Q, L255S, R261Q and E280K accounted for 0.8% each. Y356X in exon 11 accounted for 5.9%, whereas V399V accounted for 1%. R413P and A434D in exon 12 accounted for 5.9% and 2.5%, respectively ([Table 2](#t2-gmb-35-709){ref-type="table"}). Among the 16 mutations, nine were missense, three involved splice sites, two were nonsense and two involved deletions, of which H64 \> TfsX9 ([Figure 1](#f1-gmb-35-709){ref-type="fig"}) was the first to be discovered. All of these mutations have been included in the PAH Mutation Analysis Consortium Database. As shown in [Table 3](#t3-gmb-35-709){ref-type="table"}, three alleles were identified in one patient, two alleles were identified in 16 patients and the remaining cases were identified in 33 samples. Six patients with homozygous mutations were identified. The intelligence of the 25 patients in the low Phe diet intervention group is developing well while the remaining children show some degree of mental retardation.

Discussion
==========

Various PAH gene mutations have been identified in 13 exons, with those of exon 7 accounting for 20% of mutations ([@b20-gmb-35-709]; Song *et al.*, 2001; [@b3-gmb-35-709]; [@b6-gmb-35-709]). Nearly 30 species of PAH gene mutations have been found in the Chinese population and involve mainly exons 7 and 12 ([@b20-gmb-35-709]; Song *et al.*, 2001). In the present study, we identified two relatively high-frequency mutations, EX6-96A \> G and R243Q, with frequencies of 10.2% and 12.7%, respectively. Two hot spots for mutations in the PAH gene were identified in Shanxi province patients with PKU and generally agreed with the findings of previous studies ([@b23-gmb-35-709]). Several studies have shown that there is considerable regional and ethnic variation in the distribution of PAH gene mutations in China ([@b3-gmb-35-709]; [@b6-gmb-35-709]; [@b21-gmb-35-709]). In agreement with this, the frequencies of the R243Q mutation in exon 7 of the PAH gene in northern and southern China were found to be 24% and 9.5%, respectively. The frequency of R243Q in exon 7 has been reported to be 18.2% in Chinese and 12% in Koreans; in contrast, R413P is a high-frequency mutation in Japanese (30.5%) ([@b21-gmb-35-709]).

PAH mutations can be classified into disease-causing and silent mutations, depending on the extent to which enzymatic activity is affected by the mutation. In contrast to disease-causing mutations, silent mutations do not affect PAH activity. Disease-causing mutations often occur in the crosslink areas between exons or between an exon and intron and affect PAH gene transcription and translation; such interference affects protein folding and aggregation and accelerates degradation, thereby influencing the catalytic activity of PAH ([@b1-gmb-35-709]). In the present study, 16 mutations were found, including nine missense mutations, three splice site mutations and two nonsense mutations, as well as two types of deletions. The nonsense, splice site and deletion mutations interfere with protein transcription or translation and are generally considered to be pathogenic mutations. The pathogenicity of missense mutations requires further investigation involving gene expression and protein structure analysis ([@b15-gmb-35-709]). To our knowledge, this is the first report to identify the mutant site H64 \> TfsX9, a single base deletion that resulted in a frameshift mutation in exon 3 of the PAH gene. The mutation at codon 64 (c. 190), which replaces histidine by threonine, may change the PAH structure and affect the corresponding enzymatic activity.

PKU should be detected and treated early since the earlier the treatment, the better the prognosis ([@b11-gmb-35-709]). Early treatment is the key factor to changing the outcome of this disease ([@b22-gmb-35-709]). The prenatal diagnosis of PAH gene mutations using the approach described here could be useful in reducing the incidence of PKU in Shanxi province. Screening for mutations could also be useful in the detection, genetic counseling and treatment of potential PKU carriers, thereby improving the quality of life of affected individuals.

The study was supported by the Scientific and Technological Project of Shanxi Province (grant no. 20080311065) and Shanxi Provincial Health Department Project (grant no. 200705).

Associate Editor: Mara H. Hutz
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###### 

Primer sequences for PKU exons 3, 6, 7, 11 and 12.

  Exon                                      Sequences                                 Annealing temperature (°C)   Product length (bp)
  ----------------------------------------- ----------------------------------------- ---------------------------- ---------------------
  3                                         F: 5′-GTTAGGTTTTCCTGTTCTGG-3′             60                           300
  R: 5′-CTTATGTTGCAAAATTCCTC-3′                                                                                    
  6                                         F: 5′-CACAGGTTCTGGTCCCCGAC-3′             61                           354
  R: 5′-CTCTCCTCTCCTCAATCCTC-3′                                                                                    
  7                                         F: 5′-CTCCTAGTGCCTCTGACTCA-3′             60                           273
  R: 5′-CAAACCTCATTCTTGCAGCAGG-3′                                                                                  
  11                                        F: 5′-AAGGAATCGGGGTGAGATGAGAGAAGGGGC-3′   64                           357
  R: 5′-GGTACAAAGTTGCTGTAGACATTGGAGTCC-3′                                                                          
  12                                        F: 5′-ATGCCACTGAGAACTCTCTT-3′             60                           245
  R: 5′-AGTCTTCGATTACTGAGAAA-3′                                                                                    

###### 

Shanxi PAH 3, 6, 7, 11 and 12 exon mutations.

  Exon site   Amino acid change   cDNA change          Type of mutation   Number of alleles   Mutation frequency (%)
  ----------- ------------------- -------------------- ------------------ ------------------- ------------------------
  3           R111X               c\. 331C \> T        nonsense           6                   5.1
  3           H64 \> TfsX9        c\. 190delC          loss               1                   0.8
  3           S70 del             c\. 208--210delTCT   loss               1                   0.8
  6           EX6-96A \> G        c\. 611A \> G        splice site        12                  10.2
  7           R243Q               c\. 728G \> A        missense           15                  12.7
  7           G247V               c\. 740G \> T        missense           1                   0.8
  7           R252Q               c\. 755G \> A        missense           1                   0.8
  7           L255S               c\. 764T \> C        missense           1                   0.8
  7           R261Q               c\. 782G \> A        missense           1                   0.8
  7           T278I               c\. 833C \> T        missense           3                   2.5
  7           E280K               c\. 838G \> A        missense           1                   0.8
  IVS7        IVS7+2T \> A        c\. 842 +2T \> A     splice site        6                   5.1
  11          V399V               c\. 1197A \> T       splice site        6                   5.1
  11          Y356X               c\. 1068C \> A       nonsense           7                   5.9
  12          A434D               c\. 1301C \> A       missense           3                   2.5
  12          R413P               c\. 1238G \> C       missense           7                   5.9
  Number                                                                  72                  61.0
  Total                                                                   118                 100

###### 

Mutations identified in 51 PKU patients.

  Patient   Sex      Age (years)   *PHA* allele 1   *PHA* allele 2                 
  --------- -------- ------------- ---------------- ---------------- ------------- -----
  17        Male     1.5           Y356X            Het                            
  18        Male     3             Y356X            Het                            
  21        Male     5             R111X            Hom                            
  22        Female   2             R252Q            Het                            
  25        Male     2.5           H64 \> TfsX9     Het                            
  26        Female   7             T278I            Het              G247V         Het
  27        Female   7             IVS7+2T \> A     Het                            
  28        Male     6             R413P            Het                            
  33        Male     1.5           EX6-96A \> G     Het                            
  36        Male     5             EX6-96A \> G     Het                            
  37        Male     5             R111X            Het              R243Q         Het
  38        Female   4             EX6-96A \> G     Het              Y356X         Het
  40        Female   10            R413P            Het                            
  41        Male     2.5           A434D            Het                            
  47        Female   4             EX6-96A \> G     Het              R243Q         Het
  50        Male     35 days       T278I            Het              R243Q         Het
  54        Female   35 days       T278I            Het                            
  60        Male     6             R261Q            Het                            
  63        Male     2             EX6-96A \> G     Het              R413P         Het
  69        Female   1             R243Q            Het                            
  72        Female   18 days       IVS7+2T \> A     Het                            
  78        Male     7 months      R111X            Het                            
  81        Female   23 days       R243Q            Het                            
  84        Female   1             IVS7+2T \> A     Het              R243Q         Het
  87        Female   4             Y356X            Hom                            
  90        Male     3             EX6-96A \> G     Hom                            
  99        Male     15 months     V399V            Het                            
  104       Female   1             IVS7+2T \> A     Het              R413P         Het
  107       Female   1             R111X            Hom                            
  112       Female   18 days       EX6-96A \> G     Het                            
  115       Male     15 days       V399V            Het                            
  118       Male     34 days       R243Q            Het              Y356X         Het
  121       Female   1 month       R413P            Het                            
  124       Female   8 months      EX6-96A \> G     Het              R243Q         Het
  130       Female   12 months     A434D            Het                            
  132       Female   32 days       EX6-96A \> G     Het              R243Q         Het
  134       Male     34 days       IVS7+2T \> A     Het              R243Q         Het
  141       Female   4             V399V            Het              R413P         Het
  144       Male     13 months     R243Q            Het                            
  147       Male     1             IVS7+2T \> A     Het                            
  153       Male     2             R243Q            Het                            
  166       Male     6 months      Y356X            Het                            
  172       Male     1             V399V            Het                            
  175       Female   23 days       R243Q            Het              E280K V399V   Het
  180       Male     8 months      EX6-96A \> G     Het              R413P         Het
  186       Female   2.5           R413P            Het              L255S         Het
  192       Male     36 days       EX6-96A \> G     Het                            
  195       Male     43 days       S70 del                           R243Q         Het
  198       Female   11 months     V399V            Hom                            
  201       Female   4.5           A434D            Het                            
  204       Male     3.5           R243Q            Hom                            
